Assignee
CONTRAFECT CORP
US·16 granted patents·22 pending applications·29 citations·filing 2013–2023
Top patents by PatentIndex Score
38 records- 0197US10988520B2Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2020·Granted Apr 27, 2021·5 cites·20 claims
- 0294US10744189B2Lysin polypeptides active against Gram-negative bacteriaCONTRAFECT CORP·Filed 2016·Granted Aug 18, 2020·8 cites·14 claims
- 0392US11413334B2Lysin polypeptides active against Gram-negative bacteriaCONTRAFECT CORP·Filed 2020·Granted Aug 16, 2022·2 cites·13 claims
- 0486US11773140B2Gram-negative lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof in human serumCONTRAFECT CORP·Filed 2019·Granted Oct 3, 2023·3 cites·47 claims
- 0585US9499594B2Biofilm prevention, disruption and treatment with bacteriophage lysinCONTRAFECT CORP·Filed 2013·Granted Nov 22, 2016·6 cites·20 claims
- 0680US2023277617A1Biofilm prevention, disruption and treatment with bacteriophage lysinCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 0777US9718875B2Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacyCONTRAFECT CORP·Filed 2016·Granted Aug 1, 2017·2 cites·16 claims
- 0877US2023050560A1Lysin polypeptides active against gram-negative bacteriaCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 0975US9889181B2Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2013·Granted Feb 13, 2018·2 cites·12 claims
- 1072US11524046B2Biofilm prevention, disruption and treatment with bacteriophage lysinCONTRAFECT CORP·Filed 2019·Granted Dec 13, 2022·0 cites·43 claims
- 1171US12121568B2Identification of lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosaCONTRAFECT CORP·Filed 2018·Granted Oct 22, 2024·1 cites·36 claims
- 1271US2022402984A1Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 1370US2024018192A1Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2023·Application pending·0 cites
- 1469US2021128696A1Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2021·Application pending·0 cites
- 1568US11357833B2Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited therebyCONTRAFECT CORP·Filed 2016·Granted Jun 14, 2022·0 cites·17 claims
- 1668US2021008175A1Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 1766US12491245B2Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereofCONTRAFECT CORP·Filed 2021·Granted Dec 9, 2025·0 cites·23 claims
- 1866US10813983B2Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2013·Granted Oct 27, 2020·0 cites·8 claims
- 1964US2021147498A1Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in pulmonary surfactant and biofilmsCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 2061US11246928B2Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereofCONTRAFECT CORP·Filed 2019·Granted Feb 15, 2022·0 cites·35 claims
- 2161US2021363511A1Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2019·Application pending·0 cites
- 2260US2024181022A1Amurins lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteriaCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 2359US11827693B2Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacyCONTRAFECT CORP·Filed 2014·Granted Nov 28, 2023·0 cites·36 claims
- 2457US10851401B2Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptidesCONTRAFECT CORP·Filed 2017·Granted Dec 1, 2020·0 cites·16 claims
- 2556US2023277632A1MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIACONTRAFECT CORP·Filed 2021·Application pending·0 cites
- 2654US2021324359A1Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditisCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 2754US2022411473A1Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereofCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 2853US2022275061A1Therapeutic protein formulations comprising antibodies and uses thereofCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 2952US2021330738A1Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteriaCONTRAFECT CORP·Filed 2019·Application pending·0 cites
- 3052US2022401514A1Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteriaCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 3151US2022160842A1Method of treating infective endocarditisCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 3251US2022193186A1Method of treating and preventing bone and joint infectionsCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 3350US2017334974A1Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacyCONTRAFECT CORP·Filed 2017·Application pending·0 cites
- 3449US2022023399A1Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereofCONTRAFECT CORP·Filed 2018·Application pending·0 cites
- 3546US2022160843A1Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serumCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 3646US2021260070A1Lysin cf-301 resensitizes methicillin-resistant staphylococcus aureua (mrsa) to penicillin derivatives and first generation cephalosporinsCONTRAFECT CORP·Filed 2019·Application pending·0 cites
- 3746US2021032294A1MODIFIED PlySs2 LYSINS AND USES THEREOFCONTRAFECT CORP·Filed 2019·Application pending·0 cites
- 3838US10639370B2Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereofCONTRAFECT CORP·Filed 2015·Granted May 5, 2020·0 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when CONTRAFECT CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →